This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
WANG, LUHUA
| Item Type | Name |
|
Concept
|
Pyrazines
|
|
Academic Article
|
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
|
|
Academic Article
|
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
|
|
Academic Article
|
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
|
|
Academic Article
|
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
|
|
Academic Article
|
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
|
|
Academic Article
|
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
|
|
Academic Article
|
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
|
|
Academic Article
|
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
|
|
Academic Article
|
Multiple myeloma, painful neuropathy, acupuncture?
|
|
Academic Article
|
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
|
|
Academic Article
|
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
|
|
Academic Article
|
Bortezomib-resistant nuclear factor ?B expression in stem-like cells in mantle cell lymphoma.
|
|
Academic Article
|
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
|
|
Academic Article
|
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
|
|
Academic Article
|
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
|
|
Academic Article
|
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
|
|
Academic Article
|
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
|
|
Academic Article
|
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
|
|
Academic Article
|
High frequencies of response after limited primary therapy for multiple myeloma.
|
|
Academic Article
|
Value of novel agents and intensive therapy for patients with multiple myeloma.
|
|
Academic Article
|
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
|
|
Academic Article
|
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
|